Biosensor for the stratification of patients at risk of Venous Thromboembolism

Handheld Biosensor for the stratification of patients at risk of Venous Thromboembolism (VTE) This project will demonstrate the capability of a new diagnostic biosensor that provides for the first time viscoelastomeric coagulation data to stratify patients by risk of blood clot formation. The project will pilot the technology which can be applied to improve outcomes in many high mortality conditions, particularly common amongst the ageing population. Thrombotic disorders are top causes for death, either as disease states – myocardial infarction or ischemic stroke, or as potential complications to most in-hospital treatments, including childbirth and routine surgery. This collaborative project with the NIHR Diagnostic Evidence Co-operative London (DEC) will gather evidence, and generate potential new pathways alongside economic cost modelling. Managed by Highland Biosciences Ltd (HBL), the project will focus on delivering new clinical approaches to the NHS whilst generating the evidence for a highly commercially attractive value proposition for a new diagnostic business.